Annovis Bio announced that patient recruitment for the Company’s Phase 2/3 study of buntanetap for the treatment of moderate Alzheimer’s disease, or AD, remains consistent with its planned development program. To date, a total of 27 sites have now been activated and 38 patients have been screened in the Phase 2/3 study. In addition, 13 patients have been randomized to receive either one of three doses of buntanetap or placebo. Annovis will hold an R&D webcast on Thursday, April 20 to review its late-stage clinical programs in AD and Parkinson’s disease.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ANVS:
